Evaluation of the Efficacy and Safety of Rifaximin in Combination With N-acetylcysteine (NAC) in Adult Patients With Irritable Bowel Syndrome With Diarrhea
Latest Information Update: 30 Mar 2023
At a glance
- Drugs Acetylcysteine (Primary) ; Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Proof of concept; Therapeutic Use
- 06 Mar 2023 Status changed from active, no longer recruiting to completed.
- 01 Dec 2022 Results from NCT03763175 and NCT04557215; evaluating distinct gut microtypes linked to breath gas patterns in IBS-C and IBS-D subjects, published in the American Journal of Gastroenterology
- 03 Nov 2021 Planned End Date changed from 1 Sep 2021 to 31 Jan 2022.